Uploaded May 2022 | Updated November 2026, 9 hours ago
Air date: Saturday, February 12, 2022, 12PM
Description:
Data and Safety Monitoring Committees: Trials Needing DSMBs Part 4 of 4
The Introduction to the Principles and Practice of Clinical Research (IPPCR) is a course to train participants on how to effectively conduct clinical research. The course focuses on the spectrum of clinical research and the research process by highlighting epidemiologic methods, study design, protocol preparation, patient monitoring, quality assurance, and Food and Drug Administration (FDA) issues.
For more information, please visit: ocr.od.nih.gov/courses/ippcr.html
Author: Pamela Shaw, Ph.D.
Air date: Saturday, February 12, 2022, 12PM
Description:
Data and Safety Monitoring Committees: Trials Needing DSMBs Part 4 of 4
The Introduction to the Principles and Practice of Clinical Research (IPPCR) is a course to train participants on how to effectively conduct clinical research. The course focuses on the spectrum of clinical research and the research process by highlighting epidemiologic methods, study design, protocol preparation, patient monitoring, quality assurance, and Food and Drug Administration (FDA) issues.
For more information, please visit: ocr.od.nih.gov/courses/ippcr.html
Author: Pamela Shaw, Ph.D.




![Not Your Father’s Heart Disease: The Herstory and the NHLBI WISE
The research of C. Noel Bairey Merz, MD, focuses on heart disease in women, preventive cardiology, coronary physiology/pathophysiology and advanced cardiac imaging, as well as alternative and complementary medicine approaches to heart disease. Cardiovascular disease (CVD) is the leading cause of death in the US and on the planet, yet up to 70% of patients undergoing invasive angiography do not have obstructive coronary artery disease (CAD), more common in women than in men, as described by US and multi-national consensus documents. Although CMD has been documented over several decades, variability in symptom and stress testing characteristics lead to the widely held notion that these patients were “low risk”, very often receiving no specific therapy and dismissal from sub-specialty care. Evidence from the WISE original multicenter cohort, documented a higher risk of adverse events (e.g. death, myocardial infarction [MI], stroke, or hospitalization for heart failure [HF] or angina) emerging after 4-years of follow-up, comparable to patients with obstructive CAD, and higher in African American women25. Others have confirmed these findings and extended them to men (~20%). We have documented that most of these patients have coronary endothelial dysfunction, extensive but non-obstructive coronary atherosclerosis by intravascular ultrasound (IVUS), CMD, and myocardial ischemia. CMD, ischemia on stress testing, and angina persisting at 1-yr follow-up, identify patients at higher risk for adverse outcomes, most frequently hospitalization for HF, with preserved left ventricular (LV) ejection fraction (EF), i.e. HFpEF. Estimates from ACC/NCDR and WISE databases, indicate there are at least 3-4 million women and 1-2 million men in the US alone with INOCA who incur health-care costs similar to many with obstructive CAD. CMD may result from changes in function and/or structure of the coronary microcirculation, and in the absence of upstream obstructive CAD, is poorly understood mechanistically. Termed ischemia with no obstructive CAD (INOCA) and myocardial infarction with no obstructive CAD (MINOCA), these syndromes are increasingly observed in women, as well as men. Pharmacologic probe trials support anti-atherosclerotic and anti-ischemic therapies, and our ongoing clinical trial (WARRIOR NCT03417388) is testing high intensity statin, maximally-tolerated angiotensin-converting-enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) and low dose aspirin in women with INOCA for reduction of major adverse CV events (MACE); results are expected in 2025.
For more information go to https://oir.nih.gov/wals Not Your Father’s Heart Disease: The Herstory and the NHLBI WISE](https://i.ytimg.com/vi/plNCOgIPTDA/mqdefault.jpg)

![Forging a New Future: Inclusion of People with Disabilities in Technology Research and Development
Air date: Wednesday, January 11, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS]
When technology is properly created and applied it can be of tremendous benefit to people with disabilities. People with disabilities along with their allies know better than any other how being involved in the planning from day one is critical to a successfully accessible product, regardless of how many years in the future it lies. Dr. Cooper will present on technologies and research that he and members of the team at the Human Engineering Research Laboratories are working on ranging from Apps, cushions, homes, robots, and wheelchairs. Dr. Cooper will also speak about innovative education programs to build research and development capacity among people with disabilities and veterans.
Dr. Rory Cooper is the founding director at the Human Engineering Research Laboratories, a VA Rehabilitation Research and Development Center of Excellence in partnership with Pitt. Also, he serves as co-director of the NSF Quality of Life Technology Engineering Research Center, a joint Pitt-Carnegie Mellon University venture.
For more information go to https://oir.nih.gov/wals
Author: Rory Cooper, Ph.D., University of Pittsburgh
Permanent link: https://videocast.nih.gov/watch=46052 Forging a New Future: Inclusion of People with Disabilities in Technology Research and Development](https://i.ytimg.com/vi/qOF6gNww1m0/mqdefault.jpg)



![Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme
Air date: Wednesday, February 1, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture [WALS]
See https://en.wikipedia.org/wiki/Helen_Blau
For more information go to https://oir.nih.gov/wals
Author: Helen Blau, Ph.D., Stanford Medicine
Permanent link: https://videocast.nih.gov/watch=46058 Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme](https://i.ytimg.com/vi/rPVoQesTplU/mqdefault.jpg)